Haloperidol showed no clear difference in leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether haloperidol changes leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (very low certainty).
Summary of findings table ‐ Continuation may leads to lower leaving the study early due to any reason – overall acceptability… compared with reduction of polypharmacy (low certainty).
It is very uncertain whether summary of findings table ‐ CBT without antipsychotics changes leaving the study early ‐ for any reason ‐ overall acceptability… compared with CBT plus antipsychotics (very low certainty).
Summary of findings table ‐ CBT without antipsychotics showed no clear difference in leaving the study early ‐ for any reason ‐ overall acceptability… compared with no specific treatment (low certainty).
It is very uncertain whether summary of findings table ‐ CBT without antipsychotics changes leaving the study early ‐ for any reason ‐ overall acceptability… compared with antipsychotics (very low certainty).
Donepezil 23 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 10 mg/day (moderate certainty).
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 5 mg/day (moderate certainty).
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).
Rivastigmine probably leads to higher acceptability of treatment (as measured by withdrawals from trials… compared with placebo (moderate certainty).
It is very uncertain whether CLOZAPINE + RISPERIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) (very low certainty).
It is very uncertain whether CLOZAPINE + ARIPIPRAZOLE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + HALOPERIDOL (Cipriani 2013) (very low certainty).
It is very uncertain whether summary of findings: Specialist inpatient care for weight restoration changes acceptability: number of participants who completed treatment (at… compared with active outpatient or combination brief hospital/outpatient care (very low certainty).